We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Eli Lilly has begun a phase 3 trial of its monoclonal antibody LY-CoV555 for the prevention of COVID-19 in residents and staff at long-term care facilities. Read More
Merck said it plans to launch two large phase 3 trials of its oral COVID-19 antiviral candidate MK-4482 in September and is also moving ahead with trials of two potential vaccines. Read More
Roche’s rheumatoid arthritis blockbuster Actemra (tocilizumab) showed no benefit for hospitalized COVID-19 patients in a phase 3 trial, but the company still has high hopes for the drug as a potential treatment for COVID-19 infections. Read More
AstraZeneca is expanding its oncology product portfolio with a $6 billion development and commercialization agreement for Daiichi Sankyo’s investigational cancer treatment DS-1062. Read More
Pfizer and BioNTech began a phase 2/3 trial yesterday of one of their COVID-19 vaccine candidates, but not the one originally considered to be the most promising. Read More